SaferSkin

About

Our labs serve you with up-to-date in vitro assays, computational toxicology and PBPK methods, consumer testing, and regulatory toxicology assessments. Our mission and expertise is to ensure consumer safety by identifying potential dangers in your chemical formulations and evaluating the safety of your finished products.

We will provide step-by step assistance for your projects in cosmetic and pharmaceutical development – while maintaining full compliance with all regulatory requirements. At your disposal is a diverse portfolio of assays and methods, ranging from the well-established to the most cutting-edge.

All techniques meet the stringent criteria of modern science and are performed to the highest professional standard. We are devoted to providing an excellent, transparent and personalized service.

SaferSkin Workflow - An example

SaferSkin (OECD TG 497) Decision tree to be used for the 2o3 DA, taking into account borderline results.

Note: Borderline results are determined based on workflows given in Annex 1:

«The use of information elements is dictated by the limitations as found in the respective test guidelines (TG 442C, Appendix 1; TG 442D, Appendix 1A; TG 442E, Annex 1). For example, in case a negative h-CLAT result is obtained for a chemical with Log P > 3.5 (according to the limitation described in TG 442E (4)), a 2o3 DA prediction can only be made if the outcomes of the other two test methods composing the 2o3 DA are concordant and are non-borderline.»

SaferSkin Case Studies -

> Here are several case studies where we compared the results of different approaches including DAs from OECD TG 497.

Our solutions

In silico modelling

Our in silico modelling and in vitro testing workflows are anchored to key events of Adverse Outcome Pathways (AOPs).

We can apply a variety of algorithms and machine learning techniques to SaferSkin™ datasets supporting the building of reference and customised models.

For skin sensitization we have reproduced the leading defined approaches developed and used at industry leaders such as P&G, BASF, Givaudan and Shiseido and including a well-documented and easy-to-use comparison of model results.

AI / Machine learning

We have leading expertise in developing and validating QSAR models.

We apply our machine learning expertise to the development of models in SaferSkin™ applications including customised versions for customers.

Our AI team has competency in extracting targeted knowledge from information collections (documents, abstracts etc.) and organising it as structured information e.g., available to applications from a customised EdelweissData™ instance.

Data Management

Our EdelweissData™ approach to data management organises all data within our system using best data practices and standards.

All metadata and data is harmonised and aims for completeness and integrity.

Data processing workflows are organised as reproducible in silico protocols with instances stored within the system for future reference.

All in silico and in vitro protocols are fully described and stored in the system.

Secure customer data management solutions can be provided through premium customer accounts on a secure cloud.

Partner contribution

PKDERM

Created in 2018, PKDERM relies on the expertise of more than 20 years of its founder, Dr. Hanan Osman-Ponchet. As a former leader in metabolism and pharmacokinetic for large pharmaceutical companies, PKDERM’s CEO has developed and tested many alternatives to animal experiment models allowing a reliable and secure evolution from in-vivo experimentation to in-vitro experimentation.

> Read more

SenzaGen

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract.

> Read more

Curio Biotech

Founded in Jan 2017, Curio Biotech Ltd is a GLP ready Swiss Contract Research Organization (CRO) located at BioArk (biotech park), Visp, Switzerland. It provides in vitro testing services to Cosmetic, Pharma (small and large molecules) and Diagnostic industries using proprietary culture media and primary human cell based 3D co-culture models. In vitro services focus on basic research, drug discovery, toxicity, pharmacology in the areas of Dermatology, Immuno-oncology and Regenerative Medicine. Furthermore, Curio Biotech offers a variety of batch/lot release tests like potency tests for Bio-pharma industry, Biocompatibility tests and other regulatory OECD tests.

Biopredic

Biopredic International is a French privately-owned biotechnology company founded in 1993. Biopredic’s expertise was initially based on primary hepatocyte cryopreservation and quickly grew to encompass the isolation, production, and distribution of fresh and frozen human and animal biological products, including tissues, primary cells, cell lines, and reagents.

> Read more

Eurosafe

Eurosafe is a GLP-certified (A level) Contract Research Organisation (CRO), specialised in the testing of human and animal pharmaceutical products, cosmetics (ingredients and finished goods), food supplements, medical devices and biocides. Eurosafe provides state-of-the-art in-vitro ADME tests for chemical compounds, safety tests, in-vivo efficacy and tolerance studies, toxicological expertise as well as consulting services on the European regulations. Eurosafe is one unique CRO that covers several services organized around 3 specialties: 1. In vitro assays. 2. Tests on volunteers. 3. Toxicological expertise and regulations.

> Read more

React4Life

React4life is an Italian biotech company founded in 2016 after more than 15 years of R&D by Silvia Scaglione and Maurizio Aiello, together with a multidisciplinary team of experts, with the ambition to turn the promise of biomedical research into concrete benefits for society. Scientists can finally rely on a new enabling technology to recapitulate human biology in the lab: MIVO® (Multi In Vitro Organ), the next generation of organ-on-a-chip. This cutting-edge microphysiological system enables researchers to overcome the limits of current in vitro assays and animal models. It improves the reliability and predictivity of several applications: pharmaceutical drug-testing, personalized medicine, novel immuno-oncology therapies, cosmetics, dermatology, and nutraceutical.

> Read more

EdelweissConnect

Edelweiss Connect (EwC) - as the provider of this SaferWorldbyDesign platform - offers the expertise and experience to initiate, coordinate and manage large collaborative research projects, with partners from industry, government, and academia. Our goal is to incubate high-impact products, services, and solutions at the forefront of innovation, with sustainability and responsibility.

> Read more

In vitro testing

In vitro sensitization assay testing according to OECD guidelines and GLP standards

Our laboratories historically specialize in in vitro studies. We offer a portfolio of assays ranging from the well-established to the most cutting-edge, guided by in silico modelling.

Some assays are regulatory compliant to ensure safety and tolerance of finished cosmetic products. We can evaluate dermal absorption and delivery of a test substance using excised skin.

In order to determine the possibility of peripheral effects during dermal administration of test compounds, it is essential to evaluate the potential of transcutaneous passage of compounds. Our in vitro methods can measure the diffusion of chemicals across different skin models. Transcriptomics experiments can reduce the uncertainty in assay results using mechanistic gene signature analysis.

Available assays are

• > PrediSkin
• > DPRA
• > KeratinoSens™
• > h-CLAT
• > SENS-IS
• > GARD™

SaferSkin Formulation testing

With the SaferSkin Formulation testing solution we provide:

• Strong business cases supporting value gains for data-driven decisions supported by weight of evidence.
• Evaluation of uncertainty in current assessment based on Bayesian Network and AI methods.
• Business Case workflow for use of New Approach Methods (NAMs), Integrated Approaches to Testing and Assessment (IATAs) and Read Across to reduce uncertainties in recommended safe level of use of ingredients in formulation.
• Integrated Testing of key ingredients and formulations available in workflows orchestrating remote testing and return of data, models and reports to system.

SaferSkin Case Studies

SaferSkin successfully provides skin sensitization assessment using advanced defined approaches such as Bayesian Networks, regression, and 2 out of 3 Weight of Evidence (WoE). We also work with partners in a process to include advanced assays such as SENS-IS and GARD assays. Using SaferSkin characterization of chemicals can be achieved using different approaches and comparative information is provided for better decision making and risk assessment. Here are several case studies where we compared the results of different approaches including DAs from OECD TG 497.

> Click here for SaferSkin Case Studies

Prediskin

Protocols

Prediskin is able to assess, using fresh human skin discs, the potential cutaneous irritation of a cosmetic product related to its toxic effect on skin cells and its condition of exposure.

> Learn more.

Data Analysis

A notebook which demonstrates how Prediskin assay data published in the EdelweissData can be accessed and analysed.

> Learn more.

Prediskin Assay

To ensure transparency and reproducibility of data management in a Prediskin assay we employed our EdelweissData solution.

> Learn more.

Prediskin Shop

Order Skin disks, in vitro or in vivo assays, Regulatory toxicology services.

> Learn more.

The SaferSkin Application

The SaferSkin application is a web application, which is used for predicting ingredient’s potential to cause skin sensitisation, without animal testing. It applies integrated strategies of safety assessment to skin sensitisation and combines the top three approaches for accurate predictions of skin sensitisation.The application applies state-of-the-art science to workflows over the entire discovery and development funnel, to regulatory acceptance and registration. For more information see the «SaferSkin application» section on this page.

The SaferSkin Application

• The SaferSkin application is a web application, which is used for predicting ingredient’s potential to cause skin sensitisation, without animal testing.
• The application applies integrated strategies of safety assessment to skin sensitisation.
• It combines the top three approaches for accurate predictions of skin sensitisation.
• The application applies state-of-the-art science to workflows over the entire discovery and development funnel, to regulatory acceptance and registration.

Check the science behind the app > here.

The app can be used for:

• Hazard identification, classification, and labeling under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS) scheme (UN 2013).
• Quantitative risk assessment (QRA) especially when combined with in vivo evidence on analogs.
• Development of an efficient testing strategy, as a decision strategy tool.

Main features

• Comparison of 3 approaches: Bayesian Network, ‘2 out of 3 weight of evidence’, multiple regression
• Category prediction with confidence levels
• Simple to use interface
• Single compound input submission - entered as SMILES or drawn
• Physical properties calculated
• LLNA pEC3 & EC3 values from 50-90th percentile confidence

The application

> Read more

> Read more

To ensure scientific integrity we apply our services under the newest authority regulations. With this we operate under the highest ethical standards to guarantee results with highest value.

• OECD GuidelineNo. 497 on Defined Approaches for Skin Sensitisation
• OECD Test Guideline No. 442C In Chemico Skin Sensitisation
• OECD Test Guideline No. 442D In Vitro Skin Sensitisation
• OECD Test Guideline No. 442E In Vitro Skin Sensitisation